Terpos, Evangelos http://orcid.org/0000-0001-5133-1422
Ramasamy, Karthik http://orcid.org/0000-0003-3385-3707
Maouche, Nadjoua
Minarik, Jiri http://orcid.org/0000-0003-0513-326X
Ntanasis-Stathopoulos, Ioannis http://orcid.org/0000-0002-6328-9783
Katodritou, Eirini
Jenner, Matthew W.
Plonkova, Hana http://orcid.org/0000-0002-0543-7987
Gavriatopoulou, Maria http://orcid.org/0000-0002-6244-1229
Vallance, Grant D.
Pika, Tomas
Kotsopoulou, Maria
Kothari, Jaimal
Jelinek, Tomas http://orcid.org/0000-0002-5467-9253
Kastritis, Efstathios
Aitchison, Robin
Dimopoulos, Meletios A. http://orcid.org/0000-0001-8990-3254
Zomas, Athanasios
Hajek, Roman http://orcid.org/0000-0001-6955-6267
Article History
Received: 8 December 2019
Accepted: 1 March 2020
First Online: 1 April 2020
Compliance with ethical standards
:
: IN-S, EKatod, TP, MK, JK, and RA declare that they have no conflict of interest. ET reports honoraria from Abbvie, Amgen, BMS, and Takeda; honoraria and research funding from Janssen; and research funding from Genesis/Celgene, GSK, and is an SC member and a DMC member. KR reports honoraria from Amgen and Janssen and honoraria and research funding from Takeda and Celgene. NM received research funding from NIHR BRC Research Education and Training Group; honorarium, consultancy fees, speaker fees, conference attendance, and a grant from Takeda UK (17077); speaker fees from Celgene and Novartis; travel and accommodation to attend conferences from Janssen; and conference registration from Abbvie. JM reports honoraria from Amgen, Takeda, BMS, and Janssen and honoraria and research funding from Celgene. MWJ reports being an advisory board member and receiving speaker fees, travel, and accommodation to attend conferences from Takeda Oncology, Celgene, and Janssen. HP reports personal fees from Amgen. MG reports honoraria from Takeda and Amgen; steering committee for Karyopharm; and research funding from Novartis. GDV reports research funding from Takeda and Jazz Pharmaceuticals. TJ reports personal fees from Amgen, Celgene, Takeda, and Janssen. EKastr reports research funding and personal fees from Amgen and Janssen and personal fees from Takeda and Genesis Pharm. MAD reports consultancy, honoraria, and other from Amgen Inc., Celgene Corporation, Janssen Biotech Inc., Onyx Pharmaceuticals, an Amgen subsidiary, and Takeda Oncology; advisory committees for Amgen Inc., Celgene Corporation, Janssen Biotech Inc., Onyx Pharmaceuticals, an Amgen subsidiary, and Takeda Oncology; consultancy for and honoraria from Novartis; and research funding from Genesis Pharma. AZ is an employee of Takeda Oncology. RH reports consultancy, honoraria, and research funding from Janssen, BMS, and Celgene; consultancy, honoraria, membership on an entity’s board of directors or advisory committees, and research funding from Amgen and Takeda; consultancy and honoraria from Abbvie and Pharma MAR; and consultancy and research funding from Novartis.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study by their individual treating physician.